Title of Presentation
“Biobanks as tools for biomarkers validation in colon cancer”
Date and Place
Dr. Vincenzo Canzonieri received his M.D from the School of Medicine at University of Catania. He attended the Residency in Anatomic Pathology at the University of Padova, the Residency in General Oncology at the University of Catania and the residency in Forensic Medicine at the University of Udine. He obtained also a mini MBA in sanitary management at the University Bocconi in Milan in 2010.
From 1999 to 2004, Dr. Canzonieri worked as Consultant Pathologst at the CRO Aviano Cancer Center, National Cancer Institute in Aviano (Pordenone) Italy. From 2005 to 2009, Dr Canzonieri became Responsible of the Pathology Department at the Aviano Cancer Center. From 2010 to 2011 Dr Canzonieri has been Co-Director of Pathology Dept. and Responsible of the Institutional Biobank of Aviano Cancer Center. From 2014, he is Director of Pathology Dept. at CRO.
Dr Canzonieri has authored numerous scientific articles and participated, as invited speaker, at many national and international congresses.
Colorectal cancer (CRC) is the third most commonly diagnosed malignant and it is biologically heterogeneous. Molecular characterization, including somatic mutations in BRAF and KRAS, microsatellite instability (MSI), and CpG island methylator phenotype (CIMP), has provided evidence of multiple tumor subtypes. Three main pathways, have been identified: the chromosomal instability (CIN); the MSI; and the CIMP. Availability of definite biomarkers from accessible samples may be an invaluable adjunct to anticipate the diagnosis, improve prognostic information, analyze tumor heterogeneity and establish therapeutic options. New technologies, such as NGS have enabled further characterization by identifying mutated genes, including well-known genes, such as APC, SMAD4, and PIK3CA as well as some that are less known, such as SOX9 or ACVR1B.. In our Pathology Department, more than 700 archived tissue samples of CRC are available. Moreover, CRO-Biobank has collected samples from 400 patients: serum, plasma-ETDA, plasma-citrate, buffy coat, more than 300 fresh tissue samples with more than 100 samples from paired metastases and healthy tissues, along with clinico-pathological parameters. The ongoing analyses have been focused on: the new antibody (VE1) to BRAF V600E for the use in IHC; the Cadherin 17 (CDH17), for CRCs with undifferentiated morphology and BTK; hypoxia-regulated genes, including carbonic anhydrase IX (CAIX); the influence of the stroma on neoplastic growth; CD55 and CD59 that are of clinical relevance for the tumor differentiation and TNM staging; dysregulated MiRNAs, as biomarker of intra-tumor heterogeneity; metastasis associated in colon cancer 1 (MACC1).